KBLP-002 is under clinical development by KoBioLabs and currently in Phase I for Asthma. According to GlobalData, Phase I drugs for Asthma have a 74% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how KBLP-002’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
KBL-693 is under development for the treatment of moderate to severe asthma and atopic dermatitis. It is administered orally. The drug candidate comprises of Lactobacillus crispatus KBL693 single strain live bacteria, which is being developed based on the microbiome metabolic disease control technology.
KoBioLabs focuses on developing microbiome-based drugs for immune, metabolic and neurological disorders. The company is investigating KBLP-001 project to treat psoriasis; KBLP-007 and KBLP-006 drugs against inflammatory bowel disease (IBD); KBLP-002 program for the treatment of asthma and atopic dermatitis; and KBLP-005 project targeting immune-oncology indications. It is also evaluating KBLP-004 drug for NASH (non-alcoholic steatohepatitis); KBLP-009 program against liver disease; and KBLP-010 project for the treatment autism spectrum disorder. KoBioLabs utilizes Smartiome technology that consists of BaxData, a human microbiome database; BaxBank, a collection of bacterial isolates from the human donor samples; and BaxPlore, an evaluation platform to develop its drugs. The company is a spin-off from Microbiome Center at Seoul National University. KoBioLabs is headquartered in Seoul, South Korea.
For a complete picture of KBLP-002’s drug-specific PTSR and LoA scores, buy the report here.